Basilea Appoints New Chief Financial Officer

BASEL, Switzerland, Nov. 4, 2013 (GLOBE NEWSWIRE) --
Basilea Pharmaceutica Ltd. (SIX: BSLN)announced today the promotion of Mr. Donato Spota to Chief Financial Officer ofthe Company, effective today. As a member of the management committee, he willbe responsible for finance, information technology, and internal services. Mr.Spota has served as Global Head of Finance and Services since February 2013.Prior to this position, Mr. Spota acted as Head of Basilea's Global Controllingsince 2002.Ronald Scott, Chief Executive Officer of Basilea, stated: "Donato Spota has beenwith the company for over ten years. He has demonstrated exceptional executionin leading Basilea's finance and controlling functions. He was instrumental inestablishing Basilea's finance organization and has been a key participant inall our major financing and partnering transactions. I am confident that withhis longstanding financial and operational experience Donato will continue tosignificantly contribute to lead our business forward."Mr. Spota holds a master degree in business administration from the Universityof Applied Sciences Nürtingen, Germany and a diploma in information technologyfrom SFBI (Staatssekretariat für Bildung, Forschung und Innovation),Switzerland. He has over 16 years of experience as a finance professional in thepharmaceutical industry, including with F. Hoffmann-La Roche prior to joiningBasilea.About BasileaBasilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed onthe SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research anddevelopment operations of its Swiss subsidiary Basilea PharmaceuticaInternational Ltd., the company focuses on innovative pharmaceutical products inthe therapeutic areas of bacterial infections, fungal infections and oncology,targeting the medical challenge of rising resistance and non-response to currenttreatment options.DisclaimerThis communication expressly or implicitly contains certain forward-lookingstatements concerning Basilea Pharmaceutica Ltd. and its business. Suchstatements involve certain known and unknown risks, uncertainties and otherfactors, which could cause the actual results, financial condition, performanceor achievements of Basilea Pharmaceutica Ltd. to be materially different fromany future results, performance or achievements expressed or implied by suchforward-looking statements. Basilea Pharmaceutica Ltd. is providing thiscommunication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, futureevents or otherwise.For further information, please contact:+-----------------------------+--------------------------------+| Media Relations             | Investor Relations             |+-----------------------------+--------------------------------+| Peer Nils Schröder, PhD     | Barbara Zink, PhD, MBA         || Head Public Relations &     | Head Corporate Development     || Corporate Communications    |                                || +41 61 606 1102             | +41 61 606 1233                || media_relations@basilea.com | investor_relations@basilea.com |+-----------------------------+--------------------------------+This press release can be downloaded from www.basilea.com.Press release (PDF): http://hugin.info/134390/R/1740094/584178.pdf[HUG#1740094]